CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Fairfax, Virginia, United States and 27 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Baltimore, Maryland, United States and 89 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Baltimore, Maryland, United States and 73 other locations
immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...
Phase 1
Baltimore, Maryland, United States and 12 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Bethesda, Maryland, United States and 186 other locations
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...
Phase 1
Bethesda, Maryland, United States and 29 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Baltimore, Maryland, United States and 55 other locations
drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non...
Phase 2
Baltimore, Maryland, United States and 2 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Baltimore, Maryland, United States and 74 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Washington, District of Columbia, United States and 18 other locations
Clinical trials
Research sites
Resources
Legal